X

Seeking Alpha Publishes Article Featuring International Stem Cell Corp. (ISCO)

International Stem Cell Corp. specializes in the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. The company was first to perfect the natural phenomenon of parthenogenesis, which utilizes unfertilized human eggs to create hpSCs. These stem cells can be immune-matched to millions of people regardless of sex or racial background, with minimal expectation of immune rejection after transplantation.

Seeking Alpha yesterday published the following article featuring ISCO: http://seekingalpha.com/article/1320381

The article titled “Curing Parkinson’s: The Alternative Approach – Is There Money To Be Made?” provides an overview of the current treatments available, a few new options under development, and the overall cost of Parkinson’s disease on our economy. ISCO took the spotlight with its parthenogenetic stem cell-based approach, which recently generated positive safety and efficacy data during placebo-controlled studies. For more information on these studies, visit http://dtg.fm/a5Xh.

Ed Liston, author of the article, wrote, “Let me quickly put a few positives for the ISCO treatment… It is a cure of the underlying disease and not mere mitigation of superficially observable symptoms… It uses cells from unfertilized eggs, therefore, there are no ethical issues associated with the cell source… The cells created using the company’s proprietary technique are designed to be compatible with the immune system of the patient and hence, are not likely to be rejected by the patient’s body upon introduction.”

Nearly 1 million Americans are currently affected by Parkinson’s disease, which is caused by the death of dopamine-generating cells in the brain. The total number of new cases of Parkinson’s detected each year in the US is approximately 60,000. According to the Parkinson’s Disease Foundation, the cost of the disease to the US economy is approximately $25 billion a year.

For more information on International Stem Cell Corp. and its hpSC technology, visit www.InternationalStemCell.com

Let us hear your thoughts: International Stem Cell Corp. Message Board

Related Post